ALS ControlVet, Zona Industrial de Tondela ZIMII, Lote 6, 3460-605, Tondela, Portugal.
CEB - Centre of Biological Engineering, University of Minho, 4710-057, Braga, Portugal.
Vet Res. 2023 Mar 22;54(1):26. doi: 10.1186/s13567-023-01157-x.
Enterotoxigenic Escherichia coli (ETEC) colonizes the intestine of young pigs causing severe diarrhoea and consequently bringing high production costs. The rise of antibiotic selective pressure together with ongoing limitations on their use, demands new strategies to tackle this pathology. The pertinence of using bacteriophages as an alternative is being explored, and in this work, the efficacy of phage vB_EcoM_FJ1 (FJ1) in reducing the load of ETEC EC43-Ph (serotype O9:H9 expressing the enterotoxin STa and two adhesins F5 and F41) was assessed. Foreseeing the oral application on piglets, FJ1 was encapsulated on calcium carbonate and alginate microparticles, thus preventing phage release under adverse conditions of the simulated gastric fluid (pH 3.0) and allowing phage availability in simulated intestinal fluid (pH 6.5). A single dose of encapsulated FJ1, provided to IPEC-1 cultured cells (from intestinal epithelium of piglets) previously infected by EC43, provided bacterial reductions of about 99.9% after 6 h. Although bacteriophage-insensitive mutants (BIMs) have emerged from treatment, the consequent fitness costs associated with this new phenotype were demonstrated, comparatively to the originating strain. The higher competence of the pig complement system to decrease BIMs' viability, the lower level of colonization of IPEC-1 cells observed with these mutants, and the increased survival rates and health index recorded in infected Galleria mellonella larvae supported this observation. Most of all, FJ1 established a proof-of-concept of the efficiency of phages to fight against ETEC in piglet intestinal cells.
肠产毒性大肠杆菌(ETEC)定植于幼猪的肠道,引起严重腹泻,从而导致高生产成本。抗生素选择性压力的上升以及对其使用的持续限制,要求采取新的策略来解决这一病理学问题。噬菌体作为替代物的相关性正在被探索,在这项工作中,评估了噬菌体 vB_EcoM_FJ1(FJ1)在降低 ETEC EC43-Ph(表达肠毒素 STa 和两种黏附素 F5 和 F41 的 O9:H9 血清型)负荷方面的功效。考虑到在仔猪上的口服应用,FJ1 被包封在碳酸钙和藻酸盐微球上,从而防止在模拟胃液(pH3.0)的不利条件下释放噬菌体,并允许噬菌体在模拟肠液(pH6.5)中可用。向预先感染 EC43 的 IPEC-1 培养细胞(来自仔猪的肠上皮)单次给予包封的 FJ1,在 6 小时后可提供约 99.9%的细菌减少。尽管出现了噬菌体不敏感突变体(BIMs),但与原始菌株相比,证明了与这种新表型相关的适应成本。猪补体系统更高的活性降低了 BIMs 的活力,观察到这些突变体对 IPEC-1 细胞的定植水平较低,以及在感染的家蚕幼虫中记录的存活率和健康指数增加,支持了这一观察结果。最重要的是,FJ1 证明了噬菌体在仔猪肠道细胞中对抗 ETEC 的效率。